[des-arg9]-bradykinin tfa

[Des-Arg9]-Bradykinin is an agonist of Bradykinin (B1) receptor that displays selectivity for B1 over B2 receptors.

Lys-[Des-Arg9]Bradykinin,TFA is Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.

Lys-[Des-Arg9]Bradykinin TFA is a naturally occurring kinin that serves as a potent and highly selective agonist for the bradykinin B1 receptor, demonstrating binding affinities (K i values) of 0.12 nM, 1.7 nM, and 0.23 nM for the human, mouse, and rabbit B1 receptors, respectively. This compound exhibits low inhibitory activity on B2 receptors [1] [2].

Boc-Val-Pro-Arg-MCA TFA is a sensitive fluorescent substrate that is a thrombin substrate for the determination of trypsin-like serine protease activity.

Z-Gly-Gly-Arg-AMC TFA (66216-78-2 free base) is a thrombin-specific fluorogenic substrate for testing thrombin generation in PRP and platelet-poor plasma (PPP).

DTP3 TFA (1809784-29-9 free base) (DTP3 TFA) is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor.

CTAP(TFA) (103429-32-9 free base) is a potent, highly selective, and brain-penetrant antagonist of the μ-opioid receptor with IC50 of 3.5 nM. It displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP(TFA） (103429-32-9 free base) can be used for the study of L-DOPA-induced dyskinesia (LID)

Sar-[D-Phe8]-des-Arg9-Bradykinin acetate is a potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

(Arg)9 TFA (Peptide R9 TFA) is a cell-penetrating peptide. (Arg)9 TFA (Nona-L-arginine TFA) exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

Lys-[Des-Arg9]Bradykinin acetate is an endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.

R715 TFA(185052-09-9 free base) is a potent and selective bradykinin B1 receptor antagonist (pA2 = 8.49). Displays no activity at B2 receptors. Reduces mechanical hypernociception in a mouse model of neuropathic pain. Metabolically stable.

Arg-Gly-Asp TFA (99896-85-2(free base)) (RGD Trifluoroacetate) is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.

Lys-Bradykinin acetate is an endogenous bradykinin receptor agonist.

Angiotensin 1/2 (1-9)TFA is containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.

Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function.

[Des-Arg9]-Bradykinin ([Des-Arg9]-Bradykinin(2TFA))(2TFA) is an agonist of Bradykinin (B1) receptor.

Argipressin, des-glynh2(9)-, can effect on aggregation of blood platelets.

Bradykinin (2-9) (Des-Arg1-bradykinin) is an amino-truncated peptide compound that is a metabolite of Bradykinin. It is formed by the cleavage action of Aminopeptidase P.

Arg-gly-glu -Ser(TFA) is a RGD related polypeptide that controls the inhibition of fibrinogen binding to activated platelets by RGDS.

Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

Parasin I (TFA) is a 19-amino acid histone H2A-derived peptide isolated from the skin of the catfish, and shows antimicrobial activity[1].

FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

Gly-Arg-Gly-Asp-Ser (GRGDS) is a cell binding protein domain derived from the cell-binding region of fibronectin. Osteopontin uses this motif for cell adhesion.

Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]

Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.

This is a hypoxia-inducible factor-1 (HIF-1 a) 19-mer fragment. HIF-1 functions as master regulator of response to oxygen homeostasis. Hypoxia-induced gene expression is initiated when HIF-1 subunit is stabilized in response to a lack of oxygen. This part

Nona-L-arginine (Arg)9 acetate, a cell-penetrating peptide (CPP) consisting of 9 arginine residues, displays neuroprotective properties, with an IC50 of 0.78 μM in the glutamic acid model [1] [2].

Pyr-Arg-Thr-Lys-Arg-AMC TFA, an AMC-tagged decapeptide, is selectively cleaved by proteases including trypsin and thrombin. This AMC peptide serves as a substrate for measuring protease activity and assessing the efficacy of enzyme inhibitors [1].

Des-Arg9-[Leu8]-Bradykinin acetate is a potent antagonist of the bradykinin receptor 1 (B1R), utilized in renal fibrosis research [1].

(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide,and exhibits neuroprotective activity(IC50 of 0.78 μM, in the glutamic acid model).

Chemerin-9 (149-157) TFA is a potent CMKLR1 (chemokine-like receptor 1) agonist with anti-inflammatory properties. It activates phosphorylation of Akt and ERK and induces ROS production, beneficially modulating immune responses, adipocyte differentiation, and glucose metabolism. Additionally, it has been shown to alleviate Aβ 1-42-induced memory impairment, highlighting its therapeutic potential [1] [2] [3] [4].

Des-Gln14-Ghrelin TFA serves as a potent endogenous ligand for the growth hormone secretagogue receptor, effectively inducing increases in intracellular calcium levels ([Ca2+]i) in CHO-GHSR62 cells with an EC50 of 2.4 nM.

Arg-Gly-Glu-Ser TFA, an RGD-related peptide, serves as a control for evaluating the inhibitory activity of RGDS on fibrinogen binding to activated platelets.

Arg-Gly-Asp-Cys TFA serves as the binding motif through which fibronectin interacts with cell adhesion molecules. This compound has the ability to hinder platelet aggregation and fibrinogen binding.

TP508 TFA is a nonproteolytic thrombin peptide. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates the production of NO in human endothelial cells. It activates endothelial cells and stem cells to revascularize and regenerates tissues.

α-Helical CRF(9-41) TFA acts as a competitive antagonist for the CRF2 receptor, possessing a binding constant (K B) of approximately 100 nM. Additionally, it serves as a partial agonist for the CRF1 receptor, exhibiting a half-maximal effective concentration (EC 50) of 140 nM [1] [2].

[Des-Arg9]-Bradykinin acetate is a selective agonist of Bradykinin B1 receptor.

SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule.

Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3.

Lys-(Des-Arg9,Leu8)-Bradykinin is a selective antagonist of the bradykinin B1 receptor [1].

α-Helical CRF (9-41) is a synthetic peptide antagonist that targets corticotropin-releasing factor (CRF), effectively inhibiting CRF-induced adrenocorticotropic hormone (ACTH) release both in vitro, with isolated rat anterior pituitary cells at concentrations of 0.5 to 5 µM, and in vivo, in non-anesthetized, intact rats at doses ranging from 0.02 to 0.6 µmol/kg. Moreover, it prevents stress-induced ACTH release at a dose of 0.6 µmol/kg in rats and demonstrates the ability to enhance social interaction times in a rat model addressing nicotine-induced conditioned anxiety, in addition to decreasing binge-like ethanol consumption in mice.

ACTH (1-17) TFA is a corticotrophin analogue and an effective human melanocortin 1 (MC1) receptor agonist with Ki value of 0.21 nM.

Flagelin 22 TFA (Flagellin 22 TFA), a fragment of bacterial flagellin, is an effective elicitor in both plants and algae.

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (Cyclo RGDfC) TFA, a cyclic RGD peptide, displays a high affinity for αvβ3 integrin, effectively disrupting cell-integrin interactions. It suppresses pluripotent marker expression in embryonic stem cells (ESCs) and reduces the tumorigenic capability of mESCs in vivo, making it valuable in tumor research [1].

Arg-Gly-Asp-Ser (TFA) is an integrin-binding sequence that serves to inhibit integrin receptor function by directly and specifically binding to pro-caspase-8, pro-caspase-9, and pro-caspase-3, without interacting with pro-caspase-1 [1].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

Chemerin-9 (149-157) TFA, the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

Lactoferrin (17-41) TFA (146897-68-9 free base) is amino acids 17 to 41 fragment of lactoferrin, known as lactoferricin B. Lactoferrin (17-41) TFA (146897-68-9 free base) shows anti-fungal properties in combination of other anti-fungal agents.Candida Albicans is one of the targets of the lactoferricin B.

[Des-His1,Glu9]-Glucagon amide TFA is a potent peptide antagonist targeting the glucagon receptor, featuring a pA2 value of 7.2. It holds potential utility in diabetes pathogenesis research[1].